STAMPEDE-ing Towards Androgen Biosynthesis Inhibition for Treatment of High-Risk Hormone-Naïve Prostate Cancer: Changing the LATITUDE.

Since Dr. Huggins' 1941 Nobel prize winning finding that androgen deprivation therapy (ADT) effectively controls metastatic prostate cancer (PCa), 70 years passed before CHAARTED [1] and STAMPEDE [2] demonstrated that adding docetaxel to ADT prolongs survival in men with metastatic PCa. The de novo metastatic PCa global incidence is striking: 3% in the US, 6% across Europe, 4-10% in Latin America, and 60% in Asia-Pacific [3]. Historically, ADT has been standard of care, however most men progress to metastatic castration-resistant prostate cancer (mCRPC). This article is protected by copyright. All rights reserved.

BJU international. 2017 Oct 09 [Epub ahead of print]

Zachary Klaassen, Declan G Murphy

Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe